profile

Oncology Hero

Cullinan & Taiho Target NSCLC Filing, Maintenance Emerges in SCLC, Innate’s Antibody Sustains Lymphoma Benefit

Published 3 months ago • 1 min read

​

​

Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing

Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options.

What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024.

Why it Matters? These findings position CLN-081 as a potential new treatment standard in exon 20-mutant NSCLC, addressing a high unmet need with a differentiated safety profile.

​Read More​

Maintenance Strategy Shows Promise in Extensive-Stage Small Cell Lung Cancer

Context: Maintenance therapy has not historically played a major role in extensive-stage small cell lung cancer (ES-SCLC), where prognosis remains poor.

What's New? New trial results presented at ASCO support the addition of maintenance chemotherapy and immunotherapy as a potential new treatment paradigm, improving overall survival in ES-SCLC patients.

Why it Matters? These data could shift clinical practice toward maintenance approaches in SCLC, providing a needed advance in a disease with limited long-term treatment strategies.

​Read More​

Innate’s Anti-KIR3DL2 Antibody Shows Long-Term Activity in T-Cell Lymphoma

Context: KIR3DL2 is a novel immune target expressed in certain T-cell lymphomas, including Sézary syndrome and cutaneous T-cell lymphoma (CTCL).

What's New? At ASCO, Innate Pharma presented long-term data for its antibody lacutamab, showing sustained responses and durable disease control over 2 years in advanced CTCL patients.

Why it Matters? The findings support KIR3DL2 inhibition as a meaningful treatment option in rare T-cell lymphomas and strengthen the case for further development of lacutamab in hematologic cancers.

​Read More​

Study Strengthens Link Between PCOS and Endometrial Cancer

Context: Polycystic ovary syndrome (PCOS) has been associated with metabolic abnormalities and hormonal imbalances, but its cancer risk implications are still being clarified.

What's New? A new population study found that women with PCOS have a significantly increased risk of developing endometrial cancer, reinforcing the need for early gynecologic monitoring in this population.

Why it Matters? These findings may influence screening practices and long-term risk management in PCOS patients, especially in reproductive-age women with persistent hormonal dysregulation.

​Read More​

​

Oncology Hero

Sharing the latest updates in oncology

Read more from Oncology Hero

Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...

5 days ago • 2 min read

Regeneron Acquires 23andMe Research Division for $256M in Bankruptcy Auction Context: As 23andMe navigates Chapter 11 proceedings, key assets tied to its vast genomic database and pharma partnerships have drawn industry attention. What's New? Regeneron has secured a $256 million deal to acquire 23andMe’s therapeutics subsidiary, aiming to leverage the platform’s extensive genotypic and phenotypic data to fuel its precision medicine pipeline. Why it Matters? This acquisition gives Regeneron a...

3 months ago • 1 min read

Roche’s Itovebi Cuts Risk of Death by 33% in HER2-Positive Breast Cancer Context: HER2-positive breast cancer remains an aggressive subtype despite advances in targeted therapies. What's New? In updated data presented at ASCO, Roche’s anti-HER2 therapy Itovebi (trastuzumab duocarmazine) reduced the risk of death by 33% in pretreated HER2-positive breast cancer, significantly improving overall survival compared to standard therapies. Why it Matters? This reinforces Itovebi’s growing role in...

3 months ago • 1 min read